<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642547</url>
  </required_header>
  <id_info>
    <org_study_id>RJZLJRZB</org_study_id>
    <nct_id>NCT04642547</nct_id>
  </id_info>
  <brief_title>Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma</brief_title>
  <official_title>A Prospective Clinical Study of Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in&#xD;
      combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This&#xD;
      study will help find out if lenvatinib and gefitinib is a safe and useful combination for&#xD;
      treating patients with lenvatinib resistant hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months after the last subject is enrolled</time_frame>
    <description>The estimation of time from start of combination therapy to progression of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months after the last subject is enrolled</time_frame>
    <description>The time between initial combination therapy and the patient's death of any cause or most recent follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>6 months after the last subject is enrolled</time_frame>
    <description>Statistically describe the proportion of adverse events after treatment for each patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Molecular Targeted Therapy</condition>
  <arm_group>
    <arm_group_label>Combination therapy with Lenvatinib and Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight &gt; 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight &gt; 60Kg). Route of administration: Oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib and Gefitinib</intervention_name>
    <description>First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight &gt; 60Kg), oral.&#xD;
One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight &gt; 60Kg), oral.</description>
    <arm_group_label>Combination therapy with Lenvatinib and Gefitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1) Unlimited gender, aged 18-75 years; (2) Meets American Association for the Study of&#xD;
        Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) clinical&#xD;
        diagnostic criteria of hepatocellular carcinoma; (3) Barcelona Clinic Liver Cancer (BCLC)&#xD;
        Stage B or C, and there is at least one measurable tumor in the liver (long diameter ≥&#xD;
        1cm);(4) progressing after standard treatment; (5) Unresponsive or resistant to Lenvatinib;&#xD;
        (6) Child-Pugh A or scored 7 B; (7) Eastern Cooperative Oncology Group performance status&#xD;
        score &lt;= 1; (8) Platelet count &gt;= 60x10^9/L, Prothrombin time prolonged &lt;= 6 seconds.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) Uncorrectable coagulopathy with obvious bleeding tendency; (2) Patients need long-term&#xD;
        anticoagulant or anti platelet therapy and cannot stop the drugs; (3) Patients with&#xD;
        unstable or active ulcer or gastrointestinal bleeding; (4) Heart disease requiring&#xD;
        treatment or not well controlled high blood pressure; (5) Patients with interstitial&#xD;
        pneumonia; (6) Hepatic encephalopathy or refractory ascites requiring treatment; (7) There&#xD;
        is a clear active infection; (8) Receiving radiotherapy/chemotherapy/interventional therapy&#xD;
        for tumor within 4 weeks before the start of the study; (9) Severe insufficiency of&#xD;
        important organs, such as severe cardiopulmonary insufficiency; (10) Other accompanying&#xD;
        anti-tumor treatments; (11) The investigator assessed that the patient was unable or&#xD;
        unwilling to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Zhai, MD&amp;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renji Hospital, School of Medicine, Shanghai Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yaoping shi, MD&amp;PhD</last_name>
    <phone>+86 15800418632</phone>
    <email>shi_yaoping@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ming ding</last_name>
    <phone>+86 13501684280</phone>
    <email>dingmin0326@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bo zhai</last_name>
      <phone>+86 021-68383131</phone>
      <email>zhaiboshi@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>yaoping shi</last_name>
      <phone>+86 021-68383131</phone>
      <email>shi_yaoping@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bo Zhai, MD&amp;PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Zhai Bo</investigator_full_name>
    <investigator_title>Interventional Oncology Department</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>lenvatinib</keyword>
  <keyword>gefitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

